Abbvie raises 2025 EPS guidance to $12.09-$12.29 amid strong Skyrizi and Rinvoq growth

Earnings Call Insights: AbbVie Inc. (ABBV) Q1 2025

Management View

  • CEO Rob Michael highlighted an excellent start to 2025, with adjusted EPS of $2.46, exceeding the guidance midpoint by $0.10, and total revenues surpassing $13.3 billion, driven by a 21% growth in the ex-Humira platform. He announced a $0.10 increase

Leave a Reply

Your email address will not be published. Required fields are marked *